Coloplast A/S Q4 2026 Earnings Recap

Coloplast shares rose 17.5% after earnings, as investors responded to the company’s revised, more cautious long-term ambition alongside plans to invest in Chronic Care and U.S. growth. The reset reflects a more challenging external environment and higher investment, rather than an unchanged growth outlook.

Key Takeaways

• Revised its 2030 ambition to 5%–7% annual organic growth and mid-20s EBIT margin in constant currencies; return on invested capital is targeted at around 20% in 2029–30.
• Management cited price reforms, inflation and the U.S. biologics reimbursement change as pressures behind the revised ambition.
• Chronic Care, which accounts for more than 75% of group sales, remains the core business. U.S. Chronic Care delivered strong double-digit growth, with ostomy market share around 20%; management aims to sustain around double-digit U.S. Chronic Care momentum in 2026–27.
• Coloplast plans to increase investment in its innovation pipeline and U.S. commercial opportunities; R&D expenditure rose 13% this year, and more than 10 product launches are expected in 2026–27.
• The company is focusing Kerecis on inpatient biologics, where growth remains double digit. It expects the focused Wound & Tissue Repair model to deliver around double-digit growth and an EBIT margin above 10%; a DKK 500 million savings program is expected to have about 75% of its impact in 2026–27.